African American PharmacogenomicsThe Perera laboratory focuses on pharmacogenomics (using a patient's genome to predict drug response) in minority populations.
|
Biomarkers For Metformin ResponseThe major goal of our study is to identify the genetic loci and pathways that confer nonresponse to metformin in a large multi-ethnic cohort of T2D patients on metformin.
|
Pharmacogenomics Of Chemotherapeutic ToxicitiesThe Dolan lab is focused on improving the quality of life of cancer patients through the identification of genetic variants associated with risk for severe and persistent toxicities following chemotherapy (i.e. peripheral neuropathy, ototoxicity).
|
Pharmacogenomics Of Statin Therapy CenterThe overall objective of the Center "Pharmacogenomics of Statin Therapy" (POST) is to identify and validate biomarkers for efficacy of statin drugs in reducing risk of cardiovascular disease (CVD), and for adverse effects of statins, specifically myopathy and type 2 diabetes
|
CPML: Center For Precision Medicine In LeukemiaThe CPML is a multidisciplinary effort to build models to implement precision medicine approaches to match patients to medication regimens to maximize cure and minimize adverse effects.
|
Predicting Drug ActionOur goal is to develop robust predictors of drug response in an individual patient prior to embarking on treatment, to develop highly efficient screens to detect ADR liabilities in new drug candidates prior to investment in their development and patent harm, and to exploit an understanding of the molecular basis of drug action to rationally target available drugs.
|